Form 4: Director Kunkel Exercises ORIC Stock Options

Oric Pharmaceuticals Director Lori Anne Kunkel exercised 5,534 stock options at $3.75 per share, increasing her direct common stock holdings to 74,200 shares.

Summary

• Lori Anne Kunkel, a Director of Oric Pharmaceuticals, Inc. (ORIC), reported a transaction involving the exercise of stock options.
• The transaction, scheduled for December 4, 2025, was made pursuant to a Rule 10b5-1 plan.
• Kunkel acquired 5,534 shares of common stock upon exercising stock options at a price of $3.75 per share.
• Following this transaction, Kunkel's direct beneficial ownership of Oric Pharmaceuticals common stock will be 74,200 shares.
• The stock options had an exercise price of $3.75 and an expiration date of June 16, 2032.
• The vesting schedule for the original option grant included 20,500 shares vesting on the earlier of June 17, 2023, or the business day prior to the next annual meeting, and 1/36th of the remaining 33,200 shares vesting monthly from June 17, 2022.

Sentiment

Score: 5

Explanation: Routine insider transaction involving the exercise of stock options, reflecting standard compensation and equity ownership changes for a director. The transaction is pre-scheduled under a Rule 10b5-1 plan, making it a neutral event in terms of immediate market sentiment.

Positives

• The director's exercise of stock options and subsequent increase in direct beneficial ownership can be interpreted as a sign of continued alignment with shareholder interests and confidence in the company.

Future Outlook

The filing reports a pre-scheduled transaction set to occur on December 4, 2025, under a Rule 10b5-1 plan, indicating a planned exercise of stock options by a director. This is a forward-looking transaction for the individual, not a company-wide outlook.

Industry Context

This is a routine insider transaction, common for directors and executives who receive stock options as part of their compensation. Such transactions are typically pre-planned under Rule 10b5-1 to avoid accusations of trading on material non-public information.

Related Party Transactions

• Director Lori Anne Kunkel exercised stock options granted by Oric Pharmaceuticals, Inc., which is a standard compensation mechanism for company insiders and thus a related party transaction.

Stakeholder Impact

• Shareholders: The transaction increases the director's direct ownership, potentially signaling alignment of interests.
• Employees: No direct impact on general employees is indicated.
• Customers, Suppliers, Creditors: No direct impact is indicated.

Key Dates

Recommendation

This Form 4 reports a routine exercise of stock options by a director, which is a standard compensation event and does not provide new fundamental information to alter an investment thesis. It reflects an increase in direct ownership but is not indicative of significant operational or strategic changes that would warrant a 'buy' or 'sell' recommendation.

Keywords

Oric Pharmaceuticals, ORIC, Form 4, insider transaction, stock option exercise, director, beneficial ownership, equity, Rule 10b5-1